Journal of Cancer Research and Therapeutics

ORIGINAL ARTICLE
Year
: 2017  |  Volume : 13  |  Issue : 6  |  Page : 961--963

Cardiotoxicity associated with bortezomib: A single-center experience


Murali Krishna Gurram1, Swaroopa Pulivarthi2, Kirsten Ehresmann3, Josy Mathew4 
1 Department of Internal Medicine, HealthEast Care System, St. Paul, Minnesota, 55102, USA
2 Department of Research, HealthEast Care System, St. Paul, Minnesota, 55102, USA
3 Department of Data Science, HealthEast Care System, St. Paul, Minnesota, 55102, USA
4 Department of Oncology, HealthEast Care System, St. Paul, Minnesota, 55102, USA

Correspondence Address:
Dr. Murali Krishna Gurram
45, 10th Street West, St. Paul, Minnesota 55102
USA

Background: Studies evaluating the prevalence of cardiotoxicity associated with bortezomib are limited. We proposed this study to evaluate the prevalence of cardiotoxicity associated with bortezomib and its relation to multiple myeloma and other malignancies. Materials and Methods: This is a retrospective, chart review study. Subjects who received bortezomib at the HealthEast care system for various oncologic conditions were evaluated after obtaining IRB approval. Results: A total of 64 patients received bortezomib for various malignancies. Nine out of 64 (14%) patients developed cardiotoxicity during treatment with bortezomib, and the majority of these patients had a prior cardiac history and other cardiac risk factors. On further review, we did not find any significant causal relationship between these cardiac events and bortezomib. Conclusion: Cardiotoxicity is probably not related to bortezomib, even though there are some case reports suggestive of cardiac events related to bortezomib. Our findings need to be confirmed in multicenter, prospective studies.


How to cite this article:
Gurram MK, Pulivarthi S, Ehresmann K, Mathew J. Cardiotoxicity associated with bortezomib: A single-center experience.J Can Res Ther 2017;13:961-963


How to cite this URL:
Gurram MK, Pulivarthi S, Ehresmann K, Mathew J. Cardiotoxicity associated with bortezomib: A single-center experience. J Can Res Ther [serial online] 2017 [cited 2020 Sep 24 ];13:961-963
Available from: http://www.cancerjournal.net/article.asp?issn=0973-1482;year=2017;volume=13;issue=6;spage=961;epage=963;aulast=Gurram;type=0